Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
New words:
aducanumab, arm, arrangement, capture, CEO, Chart, CI, CLARITY, deceased, directly, dismissed, donanemab, electronic, Friedmann, good, headcount, invited, lecanemab, long, methodology, monoclonal, Nadav, prejudice, pronounced, stable, TRAILBLAZER, transmitted, vendor, washout, withdrawn
Removed:
announce, goal, past, resolution, stayed
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view